CD44 and prostate cancer: scRNA-seq analysis identified higher expression of CSC markers, EMT markers (HAS3 and its receptor CD44), and “stem-like” subclonal cell populations in ARLow/mCRPC/NEPC (PC3, PC3M, and DU145) compared with ARHigh/mCSPC (22RV1, LnCaP) prostate cancer cell lines (Fig. 1BII).